Proteases - Melanoma
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- B3941 Talabostat mesylate2 CitationTarget: DPP-4Summary: DPP4抑制剂
- A2213 17-DMAG (Alvespimycin) HCl1 Citation中文名: 阿螺旋霉素盐酸盐Target: HSP90Summary: Hsp90抑制剂
- A4413 PD 150606Target: CalpainsSummary: 非肽类钙蛋白酶抑制剂
- A4388 XL-8881 CitationTarget: HSP90Summary: Hsp90抑制剂
- A4386 Elesclomol (STA-4783)3 Citation中文名: 伊利司莫Summary: 氧化应激/细胞凋亡诱导剂
- A4064 NVP-BEP800Target: HSP90Summary: 全合成的HSP90β口服抑制剂
- A8177 PAC-11 CitationTarget: CaspasesSummary: 半胱天冬酶-3酶原激活剂